Value Based Health Care - The Future for the Health Care Sector?
Understand the basic concepts of Value Based Health Care, what it is, and why it is so important. You will get an overview of the stakeholders, the enablers, how value is created between the different stakeholders, and how this might impact the current business model of the industry.
Value Based Health Care (VBHC) is a delivery model where value is defined as the outcomes achieved for patients relative to costs. The concept behind VBHC is that the healthcare system is focused on achieving predetermined patient outcomes, whilst optimizing the use of resources through integrated healthcare.
The goal is to achieve better outcomes for patients while resources in the system are more efficiently utilized. This idea is in contrast to the current way of managing healthcare systems through activity-based financing and performance management.
A healthcare reform requires major changes
It is estimated that today up to 30 % of resources in healthcare are wasted through unnecessary procedures, inefficient management, non-response to treatment etc. VBHC recognizes that healthcare reform requires major changes in organization and strategies in how healthcare is delivered, measured and reimbursed. One of the key drivers of VBHC is the increasing need to optimize the resources that go into health care. In addition, the many opportunities in real world data and digital solutions enable better patient self-monitoring and self-care, placing the patient in a more central role.
- What is Value Based Healthcare (VBHC)?
- The theory of VBHC and public management theory
- Digital health: what is it?
- Real World Data, what is it good for, how can we use it, what restrictions are there?
- Practicing VBHC: examples from the real world
- New players and business models for industry
- The new competition, digital companies and why data is the new gold
- Impact on patients, what are patient-relevant outcomes, and how is this different from today?
This course will provide you with insight into the basic concepts of VBHC, what it is, and why it is so important. You will also get an overview of the stakeholders in VBHC: who the key players are and who the new powerful players are - currently entering the field of health care for the first time. You will learn from examples of ongoing VBHC projects. You will also learn about some of the enablers for VBHC, i.e. health care policy, real world data, and digitization. The course will also discuss how to set up VBHC projects, and how value is created between the different stakeholders. Finally the course will address how this will impact different players in the health care sector and how this might impact the current business model of the industry.
Professionals in need of interdisciplinary overview
This course is intended for people who work in healthcare, public health, the pharmaceutical, device and diagnostics industry or the public sector. For example, managers and providers in the health care sector, employees from the pharmaceutical, diagnostic, and device industry, researchers at universities or research institutions, as well as politicians at local and national level.
- Hold a relevant bachelor degree or equivalent
- Have a minimum 2 years of relevant job experience in drug development
- Be proficient in English
Find detailed information about the admission criteria.
Janine Traulsen, Associate Professor/External Lecturer, Department of Pharmacy, University of Copenhagen
Marlene Gyldmark, Head of Modelling, Outcomes Research, Statistics and Epidemiology – HTA group, F. Hoffmann-La Roche AG
Other course teachers
Stefan Larsson, Senior Partner and Managing Director, The Boston Consulting Group, Sweden
Charlotte Nørgaard, Founder, Patient in Focus and Chairperson for European Patients’ Academy (EUPATI)
Patrick Schorderet, Dr., Strategist and TEDx speaker, Price Waterhouse Coopers, Switzerland
The course also includes additional speakers.
This course is offered as an elective course in Master of Industrial Drug Development and in Master of Medicines Regulatory Affairs.
Priority is given to students enrolled on Master of Industrial Drug Development and Master of Medicines Regulatory Affairs. Once the enrolled students have been admitted to the course, the remaining seats are distributed on a first-come, first-served basis.
|Duration:||5 days on campus|
|Dates:||Currently not available|
|Frequency:||Once every year|
|Place:||University of Copenhagen, Copenhagen, Denmark
|Course fee:||22,500 DKK
Fee includes teaching, course materials, all meals during course hours and examination.
|Level and credit:||Master course; 3 ECTS|
|Examination date:||Please consult the exam schedule|
|Admission:||To be admitted, you must meet the admission criteria for Master of Industrial Drug Development|
Course dates and application deadlines are announced via the programme newsletter.
Download course curriculum